After TAGRISSO, 338 lung-cancer patients tested a combination—what happened?
HUTCHMED reported positive high-level Phase III SAFFRON results. In 338 patients with MET-driven EGFR-mutated advanced NSCLC after progression on TAGRISSO (osimertinib), ORPATHYS (savolitinib) plus TAGRISSO improved progression-free survival and overall survival versus doublet platinum chemotherapy. Safety matched known profiles with no new findings. Data will go to regulators and a medical meeting.
How this was made
The 30-second read
Why it matters
The disclosure provides a new efficacy signal (statistically significant and clinically meaningful improvements in both PFS and OS) plus a stated lack of new safety findings, supporting potential global registration discussions.
Market read
A primary Phase III readout with both PFS and OS benefits is a material catalyst for HUTCHMED’s ORPATHYS plus TAGRISSO regulatory pathway.
What to watch
Commercial impact depends on biomarker testing uptake (MET overexpression/amplification) and on how regulators and payers interpret the magnitude of PFS/OS benefit versus chemotherapy.
Background
SAFFRON is a global Phase III trial in MET-driven EGFR-mutated advanced NSCLC after progression on TAGRISSO (osimertinib), comparing ORPATHYS (savolitinib) plus TAGRISSO versus doublet platinum-based chemotherapy.
Ticker impact
HUTCHMED announced positive Phase III SAFFRON results for ORPATHYS plus TAGRISSO, showing statistically significant PFS and OS benefits in MET-driven EGFRm NSCLC after TAGRISSO progression.
Near-term upside bias on trial-readout optimism, with follow-through tied to regulator discussions and upcoming conference/regulatory filings.
The article is a primary disclosure of Phase III efficacy (PFS and OS) with no new safety findings, but it is high-level and does not include effect sizes, hazard ratios, or regulatory timing.
Market effects
Reinforces the biomarker-directed EGFR resistance strategy (MET-driven) and may lift sentiment for targeted oncology combination development.
Potentially supportive for China-listed biotech sentiment given ORPATHYS is already approved in China and the company is seeking broader registrations.
Could influence global EGFR-TKI combination competitive dynamics and regulator review expectations for MET-driven resistance after osimertinib.
Counterpoint
High-level results without disclosed effect sizes or statistical details may limit conviction until full data and regulatory submissions are available.
Key entities
- companyHUTCHMED
Announced positive high-level SAFFRON Phase III results for ORPATHYS plus TAGRISSO in MET-driven EGFRm NSCLC after TAGRISSO progression.
- drugORPATHYS (savolitinib)
Oral selective MET TKI used in combination with TAGRISSO in the SAFFRON trial.
- drugTAGRISSO (osimertinib)
Third-generation EGFR TKI used as backbone therapy in the SAFFRON trial.
- companyAstraZeneca
Joint developer and commercial partner for ORPATHYS; provided a quoted perspective on the combination’s benefit.
